Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands

Journal of Proteome Research

Volumn 8, Issue 7, 2009, Pages 3666-3674

  Meyer, Verena S ^a   Drews, Oliver ^a   Günder, Marc ^a   Hennenlotter, Jörg ^a   Rammensee, Hans Georg ^a   Stevanovic, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Brf1; CD20; CXCR4; Frizzled 6; MHC class I; MHC class II; Phosphopeptide; Phosphosite; Renal cell carcinoma; Titanium dioxide

Indexed keywords

CD20 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FRIZZLED PROTEIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PHOSPHOPEPTIDE; PHOSPHOPROTEIN; TITANIUM DIOXIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR;

ANTIGENS, CD20; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FRIZZLED RECEPTORS; GENES, MHC CLASS I; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LIGANDS; LIVER NEOPLASMS; PEPTIDES; PHOSPHOPEPTIDES; PHOSPHORYLATION; RECEPTORS, CXCR4; RECEPTORS, G-PROTEIN-COUPLED; TITANIUM;

EID: 67650345734     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr800937k     Document Type: Article

References (82)

1. Rammensee, H. G. Chemistry of peptides associated with MHC class I and class II molecules. Curr. Opin. Immunol. 1995, 7 (1), 85-96.
2. Rammensee, H. G.; Falk, K.; Rötzschke, O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 1993, 11, 213-44.
3. Princiotta, M. F.; Finzi, D.; Qian, S. B.; Gibbs, J.; Schuchmann, S.; Buttgereit, F.; Bennink, J. R.; Yewdell, J. W. Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003, 18 (3), 343-54.
4. Purcell, A. W. The peptide-loading complex and ligand selection during the assembly of HLA class I molecules. Mol. Immunol. 2000, 37 (9), 483-92.
5. Chicz, R. M.; Urban, R. G.; Gorga, J. C.; Vignali, D. A.; Lane, W. S.; Strominger, J. L. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 1993, 178 (1), 27-47.
6. Chicz, R. M.; Urban, R. G.; Lane, W. S.; Gorga, J. C.; Stern, L. J.; Vignali, D. A.; Strominger, J. L. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992, 358 (6389), 764-8.
7. Dongre, A. R.; Kovats, S.; deRoos, P.; McCormack, A. L.; Nakagawa, T.; Paharkova-Vatchkova, V.; Eng, J.; Caldwell, H.; Yates, J. R., III; Rudensky, A. Y. In vivo MHC class II presentation of cytosolic proteins revealed by rapid automated tandem mass spectrometry and functional analyses. Eur. J. Immunol. 2001, 31 (5), 1485-94.
8. Rudensky, A.; Preston-Hurlburt, P.; Hong, S. C.; Barlow, A.; Janeway, C. A., Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991, 353 (6345), 622-7.
9. Villadangos, J. A. Presentation of antigens by MHC class II molecules: getting the most out of them. Mol. Immunol. 2001, 38 (5), 329-46.
10. Suda, T.; Takahashi, T.; Golstein, P.; Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75 (6), 1169-78.
11. Shiver, J. W.; Su, L.; Henkart, P. A. Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 1992, 71 (2), 315-22.
12. Fisher, G. H.; Rosenberg, F. J.; Straus, S. E.; Dale, J. K.; Middleton, L. A.; Lin, A. Y.; Strober, W.; Lenardo, M. J.; Puck, J. M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81 (6), 935-46.
13. O'Garra, A.; Robinson, D. Development and function of T helper 1 cells. Adv. Immunol. 2004, 83, 133-62.
14. Li-Weber, M.; Krammer, P. H. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat. Rev. Immunol. 2003, 3 (7), 534-43.
15. Banchereau, J.; Palucka, A. K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 2005, 5 (4), 296-306.
16. Ostrand-Rosenberg, S. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr. Opin. Immunol. 1994, 6 (5), 722-7.
17. Wang, R. F. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens. Immunol. Rev. 2002, 188, 65-80.
18. Wang, R. F.; Zeng, G.; Johnston, S. F.; Voo, K.; Ying, H. T cell-mediated immune responses in melanoma: implications for immunotherapy. Crit. Rev. Oncol. Hematol. 2002, 43 (1), 1-11.
19. Evan, G. I.; Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411 (6835), 342-8.
20. Easty, D. J.; Bennett, D. C. Protein tyrosine kinases in malignant melanoma. Melanoma Res. 2000, 10 (5), 401-11.
21. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature 2001, 411 (6835), 355-65.
22. Andersen, M. H.; Bonfill, J. E.; Neisig, A.; Arsequell, G.; Sondergaard, I.; Valencia, G.; Neefjes, J.; Zeuthen, J.; Elliott, T.; Haurum, J. S. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J. Immunol. 1999, 163 (7), 3812-8.
23. Zarling, A. L.; Ficarro, S. B.; White, F. M.; Shabanowitz, J.; Hunt, D. F.; Engelhard, V. H. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 2000, 192 (12), 1755-62.
24. Zarling, A. L.; Polefrone, J. M.; Evans, A. M.; Mikesh, L. M.; Shabanowitz, J.; Lewis, S. T.; Engelhard, V. H.; Hunt, D. F. Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (40), 14889-94.
25. Engelhard, V. H.; Altrich-Vanlith, M.; Ostankovitch, M.; Zarling, A. L. Post-translational modifications of naturally processed MHC-binding epitopes. Curr. Opin. Immunol. 2006, 18 (1), 92-7.
26. Mohammed, F.; Cobbold, M.; Zarling, A. L.; Salim, M.; Barrett-Wilt, G. A.; Shabanowitz, J.; Hunt, D. F.; Engelhard, V. H.; Willcox, B. E. Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nat. Immunol. 2008, 9 (11), 1236-43.
27. Collins, M. O.; Yu, L.; Choudhary, J. S. Analysis of protein phosphorylation on a proteome-scale. Proteomics 2007, 7 (16), 2751-68.
28. Monneaux, F.; Lozano, J. M.; Patarroyo, M. E.; Briand, J. P.; Muller, S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur. J. Immunol. 2003, 33 (2), 287-96.
29. Schirle, M.; Keilholz, W.; Weber, B.; Gouttefangeas, C.; Dumrese, T.; Becker, H. D.; Stevanovic, S.; Rammensee, H. G. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 2000, 30 (8), 2216-25.
30. Barnstable, C. J.; Bodmer, W. F.; Brown, G.; Galfre, G.; Milstein, C.; Williams, A. F.; Ziegler, A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 1978, 14 (1), 9-20.
31. Lampson, L. A.; Levy, R. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 1980, 125 (1), 293-9.
32. Weinzierl, A. O.; Maurer, D.; Altenberend, F.; Schneiderhan-Marra, N.; Klingel, K.; Schoor, O.; Wernet, D.; Joos, T.; Rammensee, H. G.; Stevanovic, S. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res. 2008, 68 (7), 2447-54.
33. Weinzierl, A. O.; Lemmel, C.; Schoor, O.; Müller, M.; Krüger, T.; Wernet, D.; Hennenlotter, J.; Stenzl, A.; Klingel, K.; Rammensee, H. G.; Stevanovic, S. Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface. Mol. Cell. Proteomics 2007, 6 (1), 102-13.
34. Larsen, M. R.; Thingholm, T. E.; Jensen, O. N.; Roepstorff, P.; Jorgensen, T. J. Highly selective enrichment of phosphorylated peptides from peptide mixtures using titanium dioxide microcolumns. Mol. Cell. Proteomics 2005, 4 (7), 873-86.
35. Dengjel, J.; Akimov, V.; Olsen, J. V.; Bunkenborg, J.; Mann, M.; Blagoev, B.; Andersen, J. S. Quantitative proteomic assessment of very early cellular signaling events. Nat. Biotechnol. 2007, 25 (5), 566-8.
36. Lemmel, C.; Weik, S.; Eberle, U.; Dengjel, J.; Kratt, T.; Becker, H. D.; Rammensee, H. G.; Stevanovic, S. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 2004, 22 (4), 450-4.
37. Perkins, D. N.; Pappin, D. J.; Creasy, D. M.; Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20 (18), 3551-67.
38. Schmidlin, M.; Lu, M.; Leuenberger, S. A.; Stoecklin, G.; Mallaun, M.; Gross, B.; Gherzi, R.; Hess, D.; 〉Hemmings, B. A.; Moroni, C. The ARE-dependent mRNA-destabilizing activity of BRF1 is regulated by protein kinase B. EMBO J. 2004, 23 (24), 4760-9.
39. Benjamin, D.; Schmidlin, M.; Min, L.; Gross, B.; Moroni, C. BRF1 protein turnover and mRNA decay activity are regulated by protein kinase B at the same phosphorylation sites. Mol. Cell. Biol. 2006, 26 (24), 9497-507.
40. Maitra, S.; Chou, C. F.; Luber, C. A.; Lee, K. Y.; Mann, M.; Chen, C. Y. The AU-rich element mRNA decay-promoting activity of BRF1 is regulated by mitogen-activated protein kinase-activated protein kinase 2. RNA 2008, 14 (5), 950-9.
41. Stoecklin, G.; Colombi, M.; Raineri, I.; Leuenberger, S.; Mallaun, M.; Schmidlin, M.; Gross, B.; Lu, M.; Kitamura, T.; Moroni, C. Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover. EMBO J. 2002, 21 (17), 4709-18.
42. Ang, X. L.; Wade Harper, J. SCF-mediated protein degradation and cell cycle control. Oncogene 2005, 24 (17), 2860-70.
43. Shaw, G.; Kamen, R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986, 46 (5), 659-67.
44. Bakheet, T.; Frevel, M.; Williams, B. R.; Greer, W.; Khabar, K. S. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acids Res. 2001, 29 (1), 246-54.
45. Chen, C. Y.; Shyu, A. B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 1995, 20 (11), 465-70.
46. Chen, C. Y.; Xu, N.; Shyu, A. B. mRNA decay mediated by two distinct AU-rich elements from c-fos and granulocyte-macrophage colony-stimulating factor transcripts: different deadenylation kinetics and uncoupling from translation. Mol. Cell. Biol. 1995, 15 (10), 5777-88.
47. Benjamin, D.; Moroni, C. mRNA stability and cancer: an emerging link. Expert Opin. Biol. Ther. 2007, 7 (10), 1515-29.
48. Franke, T. F.; Kaplan, D. R.; Cantley, L. C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88 (4), 435-7.
49. Horiguchi, A.; Oya, M.; Uchida, A.; Marumo, K.; Murai, M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J. Urol. 2003, 169 (2), 710-3.
50. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S. I.; Puc, J.; Miliaresis, C.; Rodgers, L.; 〉McCombie, R.; Bigner, S. H.; Giovanella, B. C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M. H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275 (5308), 1943-7.
51. Kondo, K.; Yao, M.; Kobayashi, K.; Ota, S.; Yoshida, M.; Kaneko, S.; Baba, M.; Sakai, N.; Kishida, T.; Kawakami, S.; Uemura, H.; Nagashima, Y.; Nakatani, Y.; Hosaka, M. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int. J. Cancer 2001, 91 (2), 219-24.
52. Brenner, W.; Farber, G.; Herget, T.; Lehr, H. A.; Hengstler, J. G.; Thuroff, J. W. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int. J. Cancer 2002, 99 (1), 53-7.
53. Hara, S.; Oya, M.; Mizuno, R.; Horiguchi, A.; Marumo, K.; Murai, M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann. Oncol. 2005, 16 (6), 928-33.
54. Merseburger, A. S.; Hennenlotter, J.; Kuehs, U.; Simon, P.; Kruck, S.; Koch, E.; Stenzl, A.; Kuczyk, M. A. Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol. Int. 2008, 80 (4), 372-7.
55. Audic, Y.; Hartley, R. S. Post-transcriptional regulation in cancer. Biol. Cell 2004, 96 (7), 479-98.
56. Steinman, R. A. mRNA stability control: a clandestine force in normal and malignant hematopoiesis. Leukemia 2007, 21 (6), 1158-71.
57. Engelhard, V. H. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 1994, 12, 181-207.
58. Manici, S.; Sturniolo, T.; Imro, M. A.; Hammer, J.; Sinigaglia, F.; Noppen, C.; Spagnoli, G.; Mazzi, B.; Bellone, M.; Dellabona, P.; Protti, M. P. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J. Exp. Med. 1999, 189 (5), 871-6.
59. Dengjel, J.; Nastke, M. D.; Gouttefangeas, C.; Gitsioudis, G.; Schoor, O.; Altenberend, F.; Müller, M.; Kramer, B.; Missiou, A.; Sauter, M.; Hennenlotter, J.; Wernet, D.; Stenzl, A.; Rammensee, H. G.; Klingel, K.; Stevanovic, S. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin. Cancer Res. 2006, 12 (14 Pt. 1), 4163-70.
60. Tokuhara, M.; Hirai, M.; Atomi, Y.; Terada, M.; Katoh, M. Molecular cloning of human Frizzled-6. Biochem. Biophys. Res. Commun. 1998, 243 (2), 622-7.
61. Huang, H. C.; Klein, P. S. The Frizzled family: receptors for multiple signal transduction pathways. GenomeBiology 2004, 5 (7), 234.
62. Clevers, H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127 (3), 469-80.
63. Su, L. K.; Vogelstein, B.; Kinzler, K. W. Association of the APC tumor suppressor protein with catenins. Science 1993, 262 (5140), 1734-7.
64. Nishisho, I.; Nakamura, Y.; Miyoshi, Y.; Miki, Y.; Ando, H.; Horii, A.; Koyama, K.; Utsunomiya, J.; Baba, S.; Hedge, P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991, 253 (5020), 665-9.
65. Kinzler, K. W.; Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87 (2), 159-70.
66. Wallingford, J. B.; Habas, R. The developmental biology of Dishevelled: an enigmatic protein governing cell fate and cell polarity. Development 2005, 132 (20), 4421-36.
67. Golan, T.; Yaniv, A.; Bafico, A.; Liu, G.; Gazit, A. The human Frizzled 6 (HFz6) acts as a negative regulator of the canonical Wnt. beta-catenin signaling cascade. J. Biol. Chem. 2004, 279 (15), 14879-88.
68. Ahumada, A.; Slusarski, D. C.; Liu, X.; Moon, R. T.; Malbon, C. C.; Wang, H. Y. Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP. Science 2002, 298 (5600), 2006-10.
69. Katanaev, V. L.; Ponzielli, R.; Semeriva, M.; Tomlinson, A. Trimeric G protein-dependent frizzled signaling in Drosophila. Cell 2005, 120 (1), 111-22.
70. Liu, T.; DeCostanzo, A. J.; Liu, X.; Wang, H.; Hallagan, S.; Moon, R. T.; Malbon, C. C. G protein signaling from activated rat frizzled-1 to the beta-catenin-Lef-Tcf pathway. Science 2001, 292 (5522), 1718-22.
71. Ferguson, S. S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 2001, 53 (1), 1-24.
72. Orsini, M. J.; Parent, J. L.; Mundell, S. J.; Marchese, A.; Benovic, J. L. Trafficking of the HIV coreceptor CXCR4: role of arrestins and identification of residues in the C-terminal tail that mediate receptor internalization. J. Biol. Chem. 2000, 275 (33), 25876.
73. Balkwill, F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 2004, 14 (3), 171-9.
74. Zlotnik, A. Chemokines in neoplastic progression. Semin. Cancer Biol. 2004, 14 (3), 181-5.
75. Feng, Y.; Broder, C. C.; Kennedy, P. E.; Berger, E. A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272 (5263), 872-7.
76. Bleul, C. C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T. A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382 (6594), 829-33.
77. Zhang, Y. J.; Moore, J. P. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry. J. Virol. 1999, 73 (4), 3443-8.
78. Einfeld, D. A.; Brown, J. P.; Valentine, M. A.; Clark, E. A.; Ledbetter, J. A. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988, 7 (3), 711-7.
79. Szollosi, J.; Horejsi, V.; Bene, L.; Angelisova, P.; Damjanovich, S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J. Immunol. 1996, 157 (7), 2939-46.
80. Maloney, D. G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J. Clin. Oncol. 2005, 23 (26), 6421-8.
81. Edwards, J. C.; Cambridge, G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 2006, 6 (5), 394-403.
82. Cselenyi, C. S.; Jernigan, K. K.; Tahinci, E.; Thorne, C. A.; Lee, L. A.; Lee, E. LRP6 transduces a canonical Wnt signal independently of Axin degradation by inhibiting GSK3?s phosphorylation of beta-catenin. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (23), 8032-7.